P
Peptomyc
Foundational anti-MYC mini-proteins for cancer treatment
About Peptomyc
Peptomyc is a biotech startup that develops innovative cancer treatments. The company's primary focus is on creating a new generation of cell penetrating peptides (CPPs), which are small proteins that can penetrate cell membranes. These CPPs are designed to target a specific protein called Myc, which is often found in abnormal amounts in cancer cells. By targeting Myc, Peptomyc aims to create more effective cancer treatments.
Read full description
The company was established in 2014, based on the research of Dr. Soucek, who has spent over two decades studying Omomyc, currently the most effective known inhibitor of the Myc protein. Peptomyc's approach is unique in the cancer treatment market, which currently relies on methods like surgery, radiotherapy, and chemotherapy. These traditional treatments often fail due to the development of resistance in cancer cells.
Peptomyc's business model revolves around the development and commercialization of their Myc-targeting CPPs. The company's potential market is vast, given the high global incidence of cancer, which exceeds 18 million cases per year and is expected to increase by 62% over the next two decades. Despite the crucial role of the Myc protein in cancer, there are currently no Myc inhibitors available in the market, presenting a significant opportunity for Peptomyc.
In terms of revenue, Peptomyc is likely to generate income through the sale of their innovative cancer treatments to healthcare providers once they have been fully developed and approved for use.
At a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Barcelona, Spain
- Employees
- 23
- Open positions
- None listed
- Dealroom signal
- 83.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Surgery, Molecular Biology, Spinout, EIC, Headstart (EIT Health), European Health Catapult (EIT Health), European Health Catapult 2017 (EIT Health)
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jun 2023 | $0 | — | EIC Fund | — |
| GRANT✓Other financing | Jun 2023 | $2.5M | — | European Innovation Council | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Peptomyc is 810 monthly website visits, up 55.8% over the last three months. Peptomyc's team grew 9.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
CDTI
Government of Spain. Ministry of Economy, Trade and Business
Riva y Garcia Private Equity
European Union
European Commission
European Innovation Council
Series A2 investors entered at this stage
Alta Life Sciences
EIC Fund
Series B and later4 investors entered at this stage
CDTI Innvierte
HealthEquity
Aurora Science
InvierteMe,SL
Other known investors5 additional known investors
EIT Health
Vall d'Hebron University Hospital
ICREA
Vall d'Hebron Institute of Oncology
Asabys Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Peptomyc on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Peptomyc’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.